晚期子宮內膜癌術前化學治療的檢視

The role of neoadjuvant chemotherapy for advanced endometrial cancer

晚期子宮內膜癌通常以手術盡量將病灶包括淋巴腺切除，然後給予輔助性化學藥物治療。但對不能接受手術治療者，預後甚差。前曾認為未能接受手術或有轉移病灶者，手術前先以化學藥物來縮小腫瘤體積，可以再進行手術治療。即手術前化療後，再施以間隔性減積手術，此對某些選擇過的晚期子宮內膜癌患者，可能是一可行的取代治療方法，因間隔性手術時，比一開始便採積極的減積手術，更能增加減積成功率和減少手術前後併發症。

Advanced endometrial carcinoma patients usually are treated by aggressive cytoreductive surgery, followed by adjuvant chemotherapy. However, the prognosis of patients that cannot undergo surgery is extremely poor. Preoperative reduction of tumor burden by chemotherapy can facilitate surgery in patients previously considered to have and unresectable disease or metastatic lesions. Neoadjivant chemotherapy followed by interval cytoreductive surgery represents aviable alternative to primary cytoreductive surgery in select patients with advanced endometrial cancer, those patients who undergo interval cytoreductive surgery experience improved cytoreduction and decreased perioperative and postoperative complications.